Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress

Impact · against what's priced in

Eikon Therapeutics is positioned for several clinical catalysts as it presents updated Phase 2 data for EIK1001 and initial data for EIK1003, EIK1004, and EIK1005 at ESMO. These presentations provide the necessary data points to determine Phase 3 progression and dosing schedules for 2027.

EIKN+0.60

No priced-in read yet